title: Comparative immunogenicity of recombinant influenza hemagglutinin (rHA) and trivalent inactivated vaccine (TIV) among persons > or =65 years old.
abstract: Alternative substrates for influenza vaccine production are needed to ensure adequate supplies. We evaluated the relative safety and immunogenicity of recombinant hemagglutinin (rHA) or trivalent inactivated vaccine (TIV) among 869 > or =65-year-old subjects in a randomized clinical trial. Virologic surveillance for influenza-like illness (ILI) was conducted during the 2006-2007 epidemic. Vaccines were well tolerated. Seroconversion rates vs. influenza A/H1N1 and H3N2 antigens were superior in the rHA group, but were inferior vs. influenza B; however, results for influenza B are confounded since the vaccine antigens were different. ILI frequencies were low and similar in both groups. Studies assessing relative immunogenicity of vaccines using identical B Ags are warranted.
authors.affiliation: Baylor College of Medicine, Houston, TX 77030, United States. wkeitel@bcm.edu
authors.forename: W A
authors.initials: WA
authors.lastname: Keitel
authors.forename: J J
authors.initials: JJ
authors.lastname: Treanor
authors.forename: H M
authors.initials: HM
authors.lastname: El Sahly
authors.forename: A
authors.initials: A
authors.lastname: Gilbert
authors.forename: A L
authors.initials: AL
authors.lastname: Meyer
authors.forename: P A
authors.initials: PA
authors.lastname: Patriarca
authors.forename: M M
authors.initials: MM
authors.lastname: Cox
mesh_terms: D000368:Aged; D019267:Hemagglutinin Glycoproteins, Influenza Virus / Q000276:immunology*; D006801:Humans; D007252:Influenza Vaccines / Q000008:administration & dosage / Q000009:adverse effects / Q000276:immunology*; D015337:Multicenter Studies as Topic; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000009:adverse effects / Q000276:immunology*; D015164:Vaccines, Inactivated / Q000008:administration & dosage / Q000009:adverse effects / Q000276:immunology; D014614:Vaccines, Synthetic / Q000008:administration & dosage / Q000009:adverse effects / Q000276:immunology
chemical_list: D019267:Hemagglutinin Glycoproteins, Influenza Virus; D007252:Influenza Vaccines; D011994:Recombinant Proteins; D015164:Vaccines, Inactivated; D014614:Vaccines, Synthetic